Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
24.73 ^USD	+4.37%		+3.65%	+85.94%

Mar. 25	Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell	MT
Mar. 25	Dyne Therapeutics, Inc. Announces Management Changes	CI

Dyne Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 05, 2024 at 07:30 am EST

Dyne Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 66.64 million compared to USD 38.83 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 0.74 a year ago.

Diluted loss per share from continuing operations was USD 1.09 compared to USD 0.74 a year ago.

Latest news about Dyne Therapeutics, Inc.

Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell	Mar. 25	MT
Dyne Therapeutics, Inc. Announces Management Changes	Mar. 25	CI
Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes	Mar. 25	CI
Chardan Raises Price Target on Dyne Therapeutics to $31 From $20 on Increased Confidence in Lead Assets for DM1, DMD, Keeps Buy Rating	Mar. 08	MT
Piper Sandler Adjusts Price Target on Dyne Therapeutics to $29 From $27, Maintains Overweight Rating	Mar. 06	MT
Stifel Adjusts Price Target on Dyne Therapeutics to $41 From $35, Maintains Buy Rating	Mar. 06	MT
Dyne Therapeutics Insider Sold Shares Worth $1,398,347, According to a Recent SEC Filing	Mar. 05	MT
Oppenheimer Adjusts Dyne Therapeutics Price Target to $47 From $44, Maintains Outperform Rating	Mar. 05	MT
Dyne Therapeutics's Q4 Net Loss Widens; Shares Down Pre-Bell	Mar. 05	MT
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Dyne Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Dyne Therapeutics Insider Sold Shares Worth $2,895,519, According to a Recent SEC Filing	Mar. 04	MT
Dyne Therapeutics Insider Sold Shares Worth $811,865, According to a Recent SEC Filing	Mar. 04	MT
Dyne Therapeutics Insider Sold Shares Worth $357,296, According to a Recent SEC Filing	Mar. 04	MT
Dyne Therapeutics Insider Sold Shares Worth $19,626,903, According to a Recent SEC Filing	Feb. 29	MT
H.C. Wainwright Initiates Dyne Therapeutics With Buy Rating, Price Target is $36	Feb. 20	MT
Dyne Therapeutics Insider Sold Shares Worth $490,510, According to a Recent SEC Filing	Jan. 29	MT
Dyne Therapeutics Insider Sold Shares Worth $316,420, According to a Recent SEC Filing	Jan. 29	MT
Dyne Therapeutics Reportedly Mulling Options After Takeover Interest Received	Jan. 26	MT
Dyne Therapeutics Reportedly Seeing Takeover Interest, Weighing Options	Jan. 25	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	Jan. 12	MT
Dyne Therapeutics Insider Bought Shares Worth $29,999,988, According to a Recent SEC Filing	Jan. 11	MT
Dyne Therapeutics Raises $345.1 Million From Share Offering	Jan. 11	MT
Dyne Therapeutics Insider Sold Shares Worth $1,629,985, According to a Recent SEC Filing	Jan. 05	MT
Dyne Therapeutics Insider Sold Shares Worth $529,194, According to a Recent SEC Filing	Jan. 05	MT

Chart Dyne Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.73 USD

Average target price

37.56 USD

Spread / Average Target

+51.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DYNE THERAPEUTICS, INC.	+85.94%	2.13B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research